TL;DR
This review explores the intricate interplay between non-coding RNAs (ncRNAs) and the Epidermal Growth Factor Receptor (EGFR) signaling pathway in lung cancer. It highlights how ncRNAs can both promote and inhibit tumor growth and, crucially, mediate resistance to EGFR-targeted therapies, offering new avenues for precision medicine.
What Problem Does This Paper Address?
Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related deaths worldwide. While targeted therapies like EGFR tyrosine kinase inhibitors (EGFR-TKIs) have shown significant promise for patients with EGFR mutations, acquired resistance to these drugs is a major clinical challenge, limiting their long-term efficacy. The complex regulatory networks governing EGFR signaling and drug resistance are not fully understood. This paper addresses this gap by comprehensively reviewing the multifaceted roles of non-coding RNAs (ncRNAs) in regulating the EGFR pathway and driving resistance to EGFR-TKIs in lung cancer, aiming to provide insights for novel therapeutic strategies.
Methods
This paper is a review article, meaning it synthesizes and analyzes existing research rather than presenting new experimental data. The authors systematically reviewed a vast body of literature on ncRNAs (including miRNAs, lncRNAs, and circRNAs) and their interactions with the EGFR signaling pathway and EGFR-TKI resistance in lung cancer. They organized this information to build a comprehensive understanding of the regulatory mechanisms and identify potential therapeutic targets. The review integrates findings from various experimental studies, including molecular biology techniques, cell line experiments, animal models, and clinical sample analyses.
Datasets
Not discussed in the paper. As a review article, it synthesizes data from numerous published studies.
Key Insights and Ideas
- ncRNAs are key players in EGFR signaling: Beyond direct targeting of EGFR mRNA, ncRNAs can modulate EGFR activity through complex interactions with upstream and downstream proteins, forming intricate regulatory networks.
- Bidirectional regulation is common: The relationship between ncRNAs and EGFR is not one-sided. EGFR can influence ncRNA expression, and in turn, ncRNAs can feedback to regulate EGFR signaling, creating sophisticated feedback loops.
- ncRNAs are central to EGFR-TKI resistance: ncRNAs are implicated in various resistance mechanisms, including drug metabolism, epigenetic remodeling, activation of pro-survival pathways, and the maintenance of cancer stem cell characteristics.
- Context matters for ncRNA function: The same ncRNA can exhibit dual roles (oncogenic or tumor-suppressive) depending on the specific lung cancer subtype or cellular microenvironment, highlighting the complexity of their actions.
- CircRNAs are emerging players: While miRNAs and lncRNAs have been extensively studied, circular RNAs (circRNAs) are increasingly recognized for their significant roles in regulating EGFR signaling and contributing to drug resistance.
Key Results
The review details numerous specific examples of ncRNAs and their interactions:
- miRNAs: miR-34a directly targets EGFR mRNA, inhibiting proliferation. miR-146a-5p also targets EGFR, and its upregulation by certain compounds can suppress NSCLC cell growth. miR-19b targets PPP2R5E, a key regulator in the EGFR pathway. miR-21 is upregulated by EGFR with activating mutations and contributes to resistance.
- lncRNAs: lnc-MLETA1 acts as a sponge for miRNAs that target EGFR and IGF1R, promoting metastasis. lncRNA SOX2-OT competitively binds to miR-345-5p, leading to EGFR overexpression and promoting malignant transformation. AL355338 interacts with ENO1 to stabilize it and strengthen its interaction with EGFR, activating downstream pathways.
- circRNAs: Circ_0001955 sponges miR-769-5p, alleviating its inhibition of EGFR and activating the pathway. CircSMARCA5 acts as a sponge for miR-17-3p, which targets EGFR mRNA, impacting progression and metastasis. CircC190 is upregulated by EGFR signaling and promotes cell proliferation and migration.
- Resistance Mechanisms: Specific ncRNAs are linked to resistance through mechanisms like EMT (epithelial-mesenchymal transition), bypass signaling activation, and epigenetic modifications. For instance, miR-200c enhances gefitinib sensitivity by suppressing EMT, while miR-205 depletion induces erlotinib resistance.
Limitations and Future Work
The authors acknowledge several critical issues:
- Unclear functional heterogeneity: The dual roles of some ncRNAs require further investigation into spatiotemporal specificity and cell context dependency.
- Clinical translational research limitations: Most studies are confined to cellular or animal models, and large-scale clinical cohort validation for circulating ncRNAs as biomarkers is needed.
- Dynamic evolution of resistance: The transition from "drug-tolerant persistence" to "complete resistance" and the impact of tumor heterogeneity on ncRNA networks need deeper exploration.
- Technological bottlenecks: Current ncRNA detection technologies have limitations in sensitivity for low-abundance ncRNAs, and delivery systems for targeting ncRNAs in vivo require optimization.
Future research directions include:
- Integrating single-cell sequencing and spatial transcriptomics to understand cell-type-specific ncRNA functions.
- Utilizing organoid models to simulate ncRNA-EGFR interactions in drug-resistant clones.
- Developing liquid biopsy panels combining ncRNA biomarkers for dynamic monitoring of drug resistance.
- Exploring strategies that combine ncRNA-based therapies with targeted treatments.
- Developing CRISPR-based ncRNA editing tools for precise regulation and optimizing exosome carrier technology for targeted delivery.
- Fostering multilevel collaboration from basic science to clinical application for precision diagnosis and treatment.
Summary updated